AstraZeneca's stomach cancer drug doubles survival in late-stage trial
FROM THE WIRE · SEEKINGALPHA.COM
AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial, boosting oncology sales hopes.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive oncology result can strengthen expectations for the drugmaker's future sales.AI-generated summary